End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality.  At WuXi AppTec, our oligonucleotide platform offers end-to-end CRDMO services, covering everything from drug discovery to commercial manufacturing for both drug substances and drug products. Our seamless collaboration across WuXi Biology, WuXi Chemistry, and WuXi testing ensures a smooth journey from initial concept to clinical success, accelerating your development timeline with unparalleled efficiency.